Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Benbijja, Mohcine ^a,b   Mellouk, Amine ^b   Bobé, Pierre ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

As2O3 based therapy; Caspase activation; Cell death; Fas Fas ligand pathway; Leukemia; Membrane tyrosine phosphatase B220 CD45R; Membrane bound HSP70; NF B p50; T lymphocyte

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 8; CASPASE 9; CD45 ANTIGEN; FAS ANTIGEN; FAS LIGAND; GLUTATHIONE; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; MESSENGER RNA; OXYGEN; PROPIDIUM IODIDE; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; T-CELL LEUKEMIA CELL LINE; ANIMAL; CELL MEMBRANE; DRUG EFFECTS; JURKAT CELL LINE; LEUKEMIA; METABOLISM; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; T LYMPHOCYTE; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIGENS, CD45; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; CELL DEATH; CELL LINE, TUMOR; CELL MEMBRANE; HSP70 HEAT-SHOCK PROTEINS; HUMANS; JURKAT CELLS; LEUKEMIA; MICE; MICE, INBRED MRL LPR; NF-KAPPA B; OXIDES; T-LYMPHOCYTES;

EID: 84934982355     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-251     Document Type: Article

References (49)

1. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
2. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1, 339:1341-1348. 10.1056/NEJM199811053391901
3. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315-3324.
4. Lallemand-Breitenbach V, Zhu J, Chen Z, de The H: Curing APL through PML/RARA degradation by As2O3. Trends Mol Med 1, 18:36-42. 10.1016/j.molmed.2011.10.001
5. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62:3893-3903.
6. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de The H: Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 1, 10:547-555. 10.1038/ncb1717
7. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT: RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 1, 10:538-546. 10.1038/ncb1716
8. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
9. Yang CH, Kuo ML, Chen JC, Chen YC: Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1, 81:796-799. 10.1038/sj.bjc.6690766
10. Dai J, Weinberg RS, Waxman S, Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999, 93:268-277.
11. Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV: Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A 1, 101:4578-4583. 10.1073/pnas.0306687101
12. Dilda PJ, Hogg PJ: Arsenical-based cancer drugs. Cancer Treat Rev 1, 33:542-564. 10.1016/j.ctrv.2007.05.001
13. Bobé P, Bonardelle D, Benihoud K, Opolon P, Chelbi-Alix MK: Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood 1, 108:3967-3975. 10.1182/blood-2006-04-020610
14. Le Gall SM, Legrand J, Benbijja M, Safya H, Benihoud K, Kanellopoulos JM, Bobé P: Loss of P2X7 receptor plasma membrane expression and function in pathogenic B220+ double-negative T lymphocytes of autoimmune MRL/lpr mice. PLoS One 1, 7:e52161. 10.1371/journal.pone.0052161
15. Renno T, Attinger A, Rimoldi D, Hahne M, Tschopp J, MacDonald HR: Expression of B220 on activated T cell blasts precedes apoptosis. Eur J Immunol 1, 28:540-547. 10.1002/(SICI)1521-4141(199802)28:02<540::AID-IMMU540>3.0.CO;2-Y
16. Bleesing JJ, Morrow MR, Uzel G, Fleisher TA: Human T cell activation induces the expression of a novel CD45 isoform that is analogous to murine B220 and is associated with altered O-glycan synthesis and onset of apoptosis. Cell Immunol 1, 213:72-81. 10.1006/cimm.2001.1865
17. Hermiston ML, Xu Z, Weiss A: CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 1, 21:107-137. 10.1146/annurev.immunol.21.120601.140946
18. Holmes N: CD45: all is not yet crystal clear. Immunology 1, 117:145-155. 10.1111/j.1365-2567.2005.02265.x
19. Rhee I, Veillette A: Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol 1, 13:439-447. 10.1038/ni.2246
20. Klaus SJ, Sidorenko SP, Clark EA: CD45 ligation induces programmed cell death in T and B lymphocytes. J Immunol 1996, 156:2743-2753.
21. Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu FT, Baum LG: Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 1, 176:778-789. 10.4049/jimmunol.176.2.778
22. Clark MC, Baum LG: T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann N Y Acad Sci 1, 1253:58-67. 10.1111/j.1749-6632.2011.06304.x
23. Davison K, Mann KK, Waxman S, Miller WH Jr: JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 1, 103:3496-3502. 10.1182/blood-2003-05-1412
24. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, Huang P: Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 1, 278:37832-37839. 10.1074/jbc.M301546200
25. Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 1, 7:97-110. 10.1016/j.drup.2004.01.004
26. Multhoff G, Botzler C, Wiesnet M, Muller E, Meier T, Wilmanns W, Issels RD: A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 1, 61:272-279. 10.1002/ijc.2910610222
27. Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W, Hube K, Mocikat R, Dressel R, Kremmer E, Pockley AG, Friedrich L, Vigh L, Skerra A, Multhoff G: Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci U S A 1, 108:733-738. 10.1073/pnas.1016065108
28. Sancho D, Gomez M, Sanchez-Madrid F: CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 1, 26:136-140. 10.1016/j.it.2004.12.006
29. McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, Lee KP, Boise LH: Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther 2003, 2:1155-1164.
30. Scholz C, Wieder T, Starck L, Essmann F, Schulze-Osthoff K, Dorken B, Daniel PT: Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene 1, 24:1904-1913. 10.1038/sj.onc.1208233
31. Perkins ND: The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012, 12:121-132.
32. El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de The H, Bazarbachi A: Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000, 96:2849-2855.
33. Bornhauser BC, Bonapace L, Lindholm D, Martinez R, Cario G, Schrappe M, Niggli FK, Schafer BW, Bourquin JP: Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood 1, 110:2084-2091. 10.1182/blood-2006-12-060970
34. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P: The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 1, 43:432-448. 10.1016/j.molcel.2011.06.006
35. Le Gall SM, Bobé P, Reiss K, Horiuchi K, Niu XD, Lundell D, Gibb DR, Conrad D, Saftig P, Blobel CP: ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-Selectin, and tumor necrosis factor alpha. Mol Biol Cell 1, 20:1785-1794. 10.1091/mbc.E08-11-1135
36. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, Chen GQ: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1, 91:772-778. 10.1093/jnci/91.9.772
37. Michel L, Dupuy A, Jean-Louis F, Sors A, Poupon J, Viguier M, Musette P, Dubertret L, Degos L, Dombret H, Bachelez H: Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol 1, 121:881-893. 10.1046/j.1523-1747.2003.12479.x
38. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O, de The H: Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999, 93:278-283.
39. Chang J, Voorhees P, Kolesar J, Ahuja H, Sanchez F, Rodriguez G, Kim K, Werndli J, Bailey H, Kahl B: Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol 2009, 27:11-16.
40. Leung J, Pang A, Yuen WH, Kwong YL, Tse EW: Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 1, 109:740-746. 10.1182/blood-2006-04-019588
41. Gao L, Gao Y, Li X, Howell P, Kumar R, Su X, Vlassov AV, Piazza GA, Riker AI, Sun D, Xi Y: Aquaporins mediate the chemoresistance of human melanoma cells to arsenite. Mol Oncol 1, 6:81-87. 10.1016/j.molonc.2011.11.001
42. Renno T, Hahne M, Tschopp J, MacDonald HR: Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J Exp Med 1, 183:431-437. 10.1084/jem.183.2.431
43. Brooks WP, Lynes MA: Effects of hemizygous CD45 expression in the autoimmune Fasl(gld/gld) syndrome. Cell Immunol 1, 212:24-34. 10.1006/cimm.2001.1845
44. Sherman M, Multhoff G: Heat shock proteins in cancer. Ann N Y Acad Sci 1, 1113:192-201. 10.1196/annals.1391.030
45. Takayama S, Reed JC, Homma S: Heat-shock proteins as regulators of apoptosis. Oncogene 1, 22:9041-9047. 10.1038/sj.onc.1207114
46. Beere HM: "The stress of dying": the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 1, 117:2641-2651. 10.1242/jcs.01284
47. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G: Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res 1, 65:5238-5247. 10.1158/0008-5472.CAN-04-3804
48. Suto R, Srivastava PK: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1, 269:1585-1588. 10.1126/science.7545313
49. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med 1, 6:435-442. 10.1038/74697